FeesSafety
Pluang+

Fed likely to cut rates soon amid AI bubble burst and financial stability concerns.

Market News
23 Oct 2026
Seeking Alpha
View Source
Bearish
Fed likely to cut rates soon amid AI bubble burst and financial stability concerns.

The Federal Reserve is expected to shift to a more dovish stance, potentially cutting interest rates as early as next week if the S&P 500 drops sharply. This move is driven by concerns over financial stability following the burst of the AI bubble. The current economic situation is compared to early 2008, when the Fed cut rates despite rising oil prices due to early signs of a financial crisis. The upcoming Fed meeting on October 28 is anticipated to keep rates steady for now, but a cut could follow if market conditions worsen.

The Federal Reserve's potential rate cut is notable as market conditions evolve. For readers following the Financials sector, here is Pluang's market snapshot as of Oct 23, 2026 19:12 WIB: out of 142 priced stocks, 38 rose and 96 fell. Blackstone Inc (BX) traded at USD 116.72 with a 1-day change of -1.71%, while NatWest Group plc (NWG) and Mizuho Financial Group Inc. (MFG) both declined by 1.65%.

More News

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
57 minutes ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
57 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
57 minutes ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
1 hour ago
Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem Corporation reported strong Q3 2026 results with net sales of $290.7 million, up 8.6% year-over-year, and net earnings of $46.7 million, a 16% increase. Growth was driven by all three segments: Human Nutrition and Health, Animal Nutrition and...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App